New radioactive therapy targets deadly brain cancer
NCT ID NCT05109728
First seen Oct 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-stage study tests a radioactive drug called [177Lu]Lu-DOTA-TATE in people with glioblastoma, an aggressive brain cancer. For newly diagnosed patients, it is given alongside standard radiation and chemotherapy. For those with recurrent cancer, it is given alone. The main goal is to find a safe dose and check for side effects. About 65 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Col Uni Med Center New York Presby
New York, New York, 10032, United States
-
MD Anderson Cancer Center Uni of Te
Houston, Texas, 77030, United States
-
Novartis Investigative Site
Bron, 69677, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Porto, 4200-072, Portugal
-
Novartis Investigative Site
Granada, Andalusia, 18014, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53792-1615, United States
Conditions
Explore the condition pages connected to this study.